BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD6750 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD6750\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07115043-2374@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:AZD6750: Phase 1/2 readout est. (NCT07115043)
DESCRIPTION:AZD6750\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate Safety of AZD6750 in Adult Participants With Select Adva
 nced or Metastatic Solid Tumors\nEstimated primary completion: 2 October 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azd6750#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07115043
URL:https://assetmemo.bio/drug/azd6750#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
